NCT04315558

Revefenacin in Acute Respiratory Insufficiency in COPD

Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: University of California, Los Angeles · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.

Detailed description

Objective: To assess the efficacy of nebulized revefenacin in improving the lung mechanics of COPD patients with acute respiratory failure requiring invasive mechanical ventilation (MV), in comparison to a control group receiving the short-acting muscarinic antagonist ipratropium. Hypothesis: Revefenacin is as efficacious as ipratropium in improving the lung mechanics of COPD patients with acute respiratory failure. Study Design: RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.

Conditions

• COPD
• Acute Respiratory Failure

Interventions

Type	Name	Description
DRUG	Revefenacin Inhalation Solution [Yupelri]	nebulized drug comparison
DRUG	Ipratropium Bromide	nebulized drug comparison

Timeline

• Start date: 2020-11-01
• Primary completion: 2025-01-01
• Completion: 2025-01-01
• First posted: 2020-03-19
• Last updated: 2025-08-13

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study